🏅 FDA Orphan Designation
GIVLAARI
givosiran
Manufacturer: Alnylam Pharmaceuticals, Inc.
Indicated for:
Acute hepatic porphyriaOrphan
FDA-Approved Indications (1)
Acute hepatic porphyriaOrphan Designation
GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).
Indications & Usage
1 INDICATIONS AND USAGE GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHP). ( 1 )
💙 Support Programs
View all →GIVLAARI
Alnylam
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.